Evidence map›Paper›PMID 39630343›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Swallowing function in patients with spinal muscular atrophy before and after the introduction of new gene-based therapies: what has changed?

Marta Ruggiero, Gabriele Giannotta, Greta Pirani, Federica Saponaro, Maria Carmela Oliva, Camilla Ferrante, Antonio Trabacca

Abstract readReview
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marta Ruggiero *Unit for Severe Disabilities in Developmental Age and Young Adults (Developmental Neurology and Neurorehabilitation), Associazione "La Nostra Famiglia" - IRCCS "E. Medea" - Scientific Hospital for Neurorehabilitation, Brindisi, Italy.ORCID http://orcid.org/0000-0001-9038-640X
Gabriele Giannotta *Unit for Severe Disabilities in Developmental Age and Young Adults (Developmental Neurology and Neurorehabilitation), Associazione "La Nostra Famiglia" - IRCCS "E. Medea" - Scientific Hospital for Neurorehabilitation, Brindisi, Italy.ORCID http://orcid.org/0000-0002-1129-1689
Greta PiraniUnit for Severe Disabilities in Developmental Age and Young Adults (Developmental Neurology and Neurorehabilitation), Associazione "La Nostra Famiglia" - IRCCS "E. Medea" - Scientific Hospital for Neurorehabilitation, Brindisi, Italy.ORCID http://orcid.org/0000-0001-8646-8752
Federica SaponaroUnit for Severe Disabilities in Developmental Age and Young Adults (Developmental Neurology and Neurorehabilitation), Associazione "La Nostra Famiglia" - IRCCS "E. Medea" - Scientific Hospital for Neurorehabilitation, Brindisi, Italy.ORCID http://orcid.org/0009-0005-4960-1450
Maria Carmela OlivaUnit for Severe Disabilities in Developmental Age and Young Adults (Developmental Neurology and Neurorehabilitation), Associazione "La Nostra Famiglia" - IRCCS "E. Medea" - Scientific Hospital for Neurorehabilitation, Brindisi, Italy.ORCID http://orcid.org/0000-0003-2854-5638
Camilla FerranteUnit for Severe Disabilities in Developmental Age and Young Adults (Developmental Neurology and Neurorehabilitation), Associazione "La Nostra Famiglia" - IRCCS "E. Medea" - Scientific Hospital for Neurorehabilitation, Brindisi, Italy.ORCID http://orcid.org/0000-0002-1752-2177
Antonio TrabaccaScientific Institute I.R.C.C.S. "E. Medea", Scientific Direction, Via Don L. Monza 20, Bosisio Parini (LC), 23842, Italy. antonio.trabacca@lanostrafamiglia.it.ORCID http://orcid.org/0000-0003-3165-0105

Funding

PNRR PNRR-MR1-2022-12376937RICERCA CORRENTE Ricerca Corrente 2024 funds for biomedical research of The Italian Health Ministry
6 · The paper itself

Abstract

objectiveIndividuals diagnosed with Spinal Muscular Atrophy (SMA), particularly those presenting with the most severe phenotypes, have long contended with significant swallowing dysfunction. The recent emergence of efficacious advanced therapy has fundamentally altered the landscape of SMA management. By encompassing both the pre and post gene-based therapy eras within our analysis, we endeavour to elucidate the potential impact of these novel therapeutic interventions on this function.

methodsFollowing the established methodology outlined by the Joanna Briggs Institute, a scoping review was conducted. This review encompassed relevant literature published up to March 2024. Two electronic databases were searched, with additional studies identified by reviewing reference lists of pertinent articles. The search strategy employed a combination of keywords including "spinal muscular atrophy", "SMA", "swallowing", "feeding", and "nutrition". Articles were initially screened based on title and abstract, followed by a full-text review of eligible studies published in peer-reviewed English language journals.

resultsThe initial database search resulted in 462 articles, from which 23 studies were ultimately selected for analysis. Pre gene-based therapy studies revealed swallowing dysfunction as a prominent feature. Patients frequently reported challenges with chewing, choking on solids and liquids, and abnormal tongue movements during eating. Early dysphagia research relied on subjective measures (questionnaires, scales). objective measures like video fluoroscopic (VFSS) were rare. After gene-based therapies (GBTs), VFSS became the dominant, more objective method. Studies investigating the post-gene therapy era suggest potential clinical benefits, with trends towards improvement or stabilization of swallowing function.

conclusionPre gene-based therapy studies revealed widespread swallowing dysfunction in SMA. Conversely, the post-treatment era suggests potential improvement. Future research should prioritize identifying optimal therapies for individual swallowing function and develop validated assessments to optimize SMA management.

Indexed as

DeglutitionDeglutition DisordersGenetic TherapyMuscular Atrophy, SpinalHumansDysphagiaScoping reviewSpinal muscular atrophySwallowingSwallowing assessment

Identifiers

PMID39630343
PMCPMC11828825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.